PRZOOM - /newswire/ -
San Antonio, TX, United States, 2016/11/09 - AccuVein Inc. announced that it will be exhibiting at ASDS, a comprehensive meeting spanning the field of dermatologic surgery, being held in New Orleans, LA on November 10-13 - AccuVein.com.
AccuVein Inc., the global leader in vein visualization and creator of the world’s only portable, non-contact vein illumination device, announced today that it will be exhibiting at ASDS, a comprehensive meeting spanning the field of dermatologic surgery, being held in New Orleans, LA on November 10-13.
AccuVein’s flagship product, the AV400, helps healthcare professionals locate veins by displaying a map of the patient’s vasculature directly on the surface of the skin. For vascular and aesthetics clinicians, locating peripheral vasculature is invaluable for accessing veins for sclerotherapy procedures and avoiding veins in cosmetic procedures to help minimize bruising.
“AccuVein’s leading vein visualization technology is being embraced by dermatologists and aesthetic physicians around the globe,” said Mike Munzer, V.P. of Channel Management at AccuVein . “Our participation in ASDS will help us continue to make inroads in this important market.”
AccuVein will have its vein illumination technology on display at ASDS booth #150 at the Hyatt Regency New Orleans hotel.
About AccuVein, Inc.
AccuVein, Inc. (accuvein.com) is the global leader in vein visualization technology. AccuVein’s flagship product, the AV400, is the world’s only hand-held, non-contact vein illumination solution. The device has won numerous awards including the prestigious Prism Award for Photonics Innovation. It allows healthcare professionals to see a map of peripheral veins on the skin’s surface with the goal of accessing or avoiding veins. It is built on proprietary technology as embodied in its growing patent portfolio that covers a broad range of imaging and medical diagnostic technologies. AccuVein is in use at more than 3,000 facilities and available for sale in over 120 countries worldwide.